Postprandial lipemia--effect of lipid-lowering drugs
- PMID: 12044585
- DOI: 10.1016/s1567-5688(01)00004-6
Postprandial lipemia--effect of lipid-lowering drugs
Abstract
Exaggerated postprandial hyperlipidemia has been associated with cardiovascular disease. The mechanisms underlying this association are likely to depend on a multitude of effects. Potentially atherogenic remnants of triglyceride-rich lipoproteins (TRL) accumulate in the postprandial state. In addition, TRL may promote the formation of small dense LDL. There are some indications that the postprandial period is a hypercoagulable state and endothelial function seems to be hampered after acute fat intake. Conventional lipid lowering drugs such as statins and fibrates have the potency of reducing postprandial hyperlipidemia, but the fibrates seem to be more effective in this respect. There is a complete lack of prospective studies linking inefficient postprandial lipid metabolism with clinical endpoints and there is also a need to include investigations of postprandial lipid metabolism in the evaluation of novel drugs affecting lipid metabolism and insulin resistance.
Similar articles
-
Comparison in patients with type 2 diabetes of fibric acid versus hepatic hydroxymethyl glutaryl-coenzyme a reductase inhibitor treatment of combined dyslipidemia.Metabolism. 2002 Oct;51(10):1355-9. doi: 10.1053/meta.2002.34713. Metabolism. 2002. PMID: 12370858 Clinical Trial.
-
A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia.Cardiovasc Drugs Ther. 1997 Jan;10(6):787-94. doi: 10.1007/BF00053037. Cardiovasc Drugs Ther. 1997. PMID: 9110123 Clinical Trial.
-
The effect of statins on postprandial lipemia.Curr Drug Targets. 2007 Apr;8(4):551-60. doi: 10.2174/138945007780362809. Curr Drug Targets. 2007. PMID: 17430126 Review.
-
Treatment of dyslipoproteinemia in the metabolic syndrome.Exp Clin Endocrinol Diabetes. 2001;109(4):S548-59. doi: 10.1055/s-2001-15117. Exp Clin Endocrinol Diabetes. 2001. PMID: 11453042 Review.
-
Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.Am Heart J. 1999 Jul;138(1 Pt 1):151-5. doi: 10.1016/s0002-8703(99)70261-9. Am Heart J. 1999. PMID: 10385779
Cited by
-
Increased postprandial triglyceride-rich lipoprotein levels in elderly survivors of myocardial infarction.Lipids. 2008 Jun;43(6):507-15. doi: 10.1007/s11745-008-3165-6. Epub 2008 Apr 4. Lipids. 2008. PMID: 18389299
-
The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes.Diabetologia. 2005 Jan;48(1):83-95. doi: 10.1007/s00125-004-1619-9. Epub 2004 Dec 24. Diabetologia. 2005. PMID: 15619071 Clinical Trial.
-
The efficacy of Ezetimibe added to ongoing Fibrate-Statin therapy on postprandial lipid profile in the patients with type 2 Diabetes mellitus.J Diabetes Metab Disord. 2013 Jun 4;12(1):24. doi: 10.1186/2251-6581-12-24. J Diabetes Metab Disord. 2013. PMID: 23734746 Free PMC article.
-
Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation.J Lipid Res. 2009 Feb;50(2):204-13. doi: 10.1194/jlr.M700505-JLR200. Epub 2008 Sep 23. J Lipid Res. 2009. PMID: 18812596 Free PMC article.
-
Abrogation of postprandial triglyceridemia with dual PPAR α/γ agonist in type 2 diabetes mellitus: a randomized, placebo-controlled study.Acta Diabetol. 2020 Jul;57(7):809-818. doi: 10.1007/s00592-020-01487-8. Epub 2020 Feb 6. Acta Diabetol. 2020. PMID: 32030508 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical